Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $51.75.
A number of brokerages have recently weighed in on RCKT. Chardan Capital reiterated a “buy” rating and set a $62.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, August 6th. JPMorgan Chase & Co. increased their target price on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday, September 30th. Scotiabank began coverage on Rocket Pharmaceuticals in a research note on Wednesday. They set a “sector outperform” rating and a $50.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, August 6th.
Check Out Our Latest Stock Analysis on Rocket Pharmaceuticals
Hedge Funds Weigh In On Rocket Pharmaceuticals
Rocket Pharmaceuticals Stock Performance
RCKT opened at $18.82 on Tuesday. Rocket Pharmaceuticals has a 12-month low of $15.98 and a 12-month high of $32.53. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -6.56 and a beta of 1.09. The business has a 50 day moving average of $18.54 and a 200-day moving average of $21.19. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.05.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.02). During the same quarter in the prior year, the business earned ($0.82) earnings per share. On average, equities research analysts expect that Rocket Pharmaceuticals will post -2.97 earnings per share for the current year.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
- Five stocks we like better than Rocket Pharmaceuticals
- How to Use the MarketBeat Dividend Calculator
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the Nasdaq? Complete Overview with History
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.